Table 4. Clinical characteristics of... | American Society of Hematology

Table 4.

Clinical characteristics of p210^BCR-ABLpositive patients after BMT

Parameters	p190^BCR-ABL Positive	p190^BCR-ABL Negative	P^4-150
Number of patients, n = 24	14	10
Mean patient age at BMT, y	33.4 ± 13	32.7 ± 7	NS
Sex patients, male/female	6/8	3/7	NS
Mean time interval between diagnosis and BMT, mo	24.7 ± 20.8	18.3 ± 11.4	NS
Clinical phase at BMT, chronic phase/others	11/3	7/3	NS
Platelets at BMT, × 10⁹/L	335.2 ± 239.2	437.1 ± 422.8	NS
WBC at BMT, × 10⁹/L	10.1 ± 6.6	19.2 ± 22.2	NS
Preparative regimen, TBI + CY/BU + CY	10/4	7/3	NS
GVHD prophylaxis, short MTX + CsA/CsA alone	10/4	5/5	NS
T-cell depletion	6	0	.0238
Acute GVHD	1	2	NS
Chronic GVHD	1	7	.0023 (.0349)^4-151

Parameters	p190^BCR-ABL Positive	p190^BCR-ABL Negative	P^4-150
Number of patients, n = 24	14	10
Mean patient age at BMT, y	33.4 ± 13	32.7 ± 7	NS
Sex patients, male/female	6/8	3/7	NS
Mean time interval between diagnosis and BMT, mo	24.7 ± 20.8	18.3 ± 11.4	NS
Clinical phase at BMT, chronic phase/others	11/3	7/3	NS
Platelets at BMT, × 10⁹/L	335.2 ± 239.2	437.1 ± 422.8	NS
WBC at BMT, × 10⁹/L	10.1 ± 6.6	19.2 ± 22.2	NS
Preparative regimen, TBI + CY/BU + CY	10/4	7/3	NS
GVHD prophylaxis, short MTX + CsA/CsA alone	10/4	5/5	NS
T-cell depletion	6	0	.0238
Acute GVHD	1	2	NS
Chronic GVHD	1	7	.0023 (.0349)^4-151

F4-150

Indicates comparisons between continuous variables by Wilcoxon signed rank test and comparisons between frequencies by Fisher exact test. NS indicates not significant.

F4-151

Indicates that significance is derived from multivariate proportional hazards general linear model analysis.

View Large

This Feature Is Available To Subscribers Only